Sophie Schmitz

I am Managing Partner at Partners4Access, the global access experts for orphan drugs. I am heavily involved in advising orphan drug clients on price and market access strategies, with the ultimate goal of optimizing their launch. My 20 year career spans various pharmaceutical therapy areas and medical devices. During my time in industry I worked on several key product launches in both strategic planning and implementation. Managing global, regional and local teams has certainly helped me advise clients how to successfully face the real-life challenges in today’s biotech world.

Email Sophie

Stuart Tutt

I am the Performance Excellence Specialist at Partners4Access. I worked in global and European pricing and market access for over 20 years.

Following the acquisition of PriceSpective by ICON in 2012, I was successively European Head and Global Head of the Pricing and Market Access consulting team. I led consulting projects for a very large number of large, medium and small biopharma companies, across a wide range of therapy areas and all phases of development, with a focus on in-licensing evaluations, phase 3 planning, launch pricing and market access and loss of exclusivity planning. In addition I led projects advising clients on internal process and infrastructure.

During my industry tendure, I worked at GSK where responsibilities included pricing and reimbursement strategy for pipeline products, price management of marketed products and managing the in-house price database. I have a degree in mathematics from Oxford University and a master in Operational Research.

Email Stuart

Jaineel Mistry

I am a Pricing and Market Access Specialist at Partners4Access. Having worked within various global consultancies over the last 5 years I specialise in value demonstration, market access and reimbursement strategy, value communication, payer strategy and insights, launch planning, evidence generation planning, and stakeholder mapping. Throughout my time in consultancy, I have successfully advised several pharmaceutical and biotech clients on commercialising their assets, including many orphan drug assets, across several markets and led a diverse range of global projects. I am a clinical pharmacist by training having trained at St George’s Hospital, London.

Email Jaineel

Christina Poschen

I am an Associate Consultant at Partners4Access, as such I am involved in developing price and market access strategies for orphan drug clients. My expertise includes building market access and policy strategies for Life Science clients across various therapy areas. Previously, I worked in-house for a pharmaceutical company and for a trade association representing small and medium sized bio tech companies and as well as in consulting in global and regional level.

Email Christina

Aparna Krishnan

I am Corporate Affairs Lead at Partners4Access with a decade’s experience in the pharmaceutical and healthcare industry. My primary focus is on strategic corporate engagement planning, operations, brand awareness, marketing and social media campaigns. I have previously worked with several global pharmaceutical consulting and business intelligence firms focusing on market access, pricing and reimbursement. I have a LifeSciences Bachelor degree and a Masters in International Finance, with a focus on econometric modelling on the pharmaceutical industry.

Email Aparna

Nader Murad

I am a Senior Analyst at Partners4Access with experience in competitive landscape assessments, stakeholder mapping and commercial analysis for the pharmaceutical industry. Prior to joining P4A, I worked as an analyst at one of the industry’s leading competitive intelligence firms.

I covered multiple therapy areas including, but not limited to, meningococcal vaccines, immuno-oncology, ophthalmology and rare diseases. I have an undergraduate degree in International Business Studies and a postgraduate degree in International Healthcare management. I am fluent English and Arabic

Email Nader

Joanna Fernandes

I am an analyst at Partners4Access, and am involved in developing treatment landscape assessments and global market access strategies for orphan drug and pharmaceutical companies. I have completed a B.Sc. in Biochemistry at Imperial College London, focusing on infectious diseases and biotechnology. Previously, I worked as an interim-analyst at Finalta, Mckinsey Solutions, which has helped me develop my primary and secondary research skills. Since starting at Partners4Access, I have worked on a number of projects across a range of therapy areas, including oncology and gene therapy.

Email Joanna

Maximus Rex

I am an analyst at Partners4Access working on a range of projects including primary and secondary research, value messages and corporate war games to support the development of market access strategies for clients in the biotechnology and pharmaceutical industries. Prior to joining P4A, I worked as an interim-analyst at McKinsey, having previously completed a Research Master’s in Molecular and Cellular Biosciences and a BSc in Biochemistry at Imperial College London.

Email Max


Preeti Patel, GPI

I am clinical pharmacist with over 15 years of experience in pricing and reimbursement systems and solutions and have directed engagements throughout Europe, BRIC, and Asia, creating solutions to some of the most challenging business situations. I have led and directed teams on a variety of strategic and implementation projects and is passionate about helping companies resolve pricing challenges by championing the use of innovative solutions. I head up Global Pricing Innovations, GPI, who have a strategic partnership with P4A to support price modelling and competitor insights. Prior to setting up GPI, I worked as a VP at a US consulting firm heading up the global pricing practice.

Gianluca Funeri, GPI

I am a market access, pricing & health economics expert with 15 years’ experience in market access both from a strategic consulting and pharmaceutical industry perspective. I supported clients to define market access strategies for the launch of pharmaceutical products and medical devices. My key expertise lie within pricing and health economic modelling and I have supported clients in a number of projects focused on price-revenue optimization and on health technology assessment, cost-effectiveness analysis, and budget impact analysis.

Julie Brennan, Verto Health

As an associate to Partners4Access, I provide an in-depth understanding of the complex matrix that determines optimal market access in the U.K. I have spent the last 20 years working in the pharmaceutical industry as part of numerous commercialisation and launch execution teams and latterly as a consultant supporting clients to achieve the optimal access for their assets. I am passionate about bringing the strategy to life through excellence in HTA planning and implementation, value communications and payer-stakeholder engagement.

Anthony G. Bower, PhD, BRG LLC

I am president of the consultancy BRG LLC. The firm focuses on improving commercial effectiveness via insights and actions implemented at the executive level. The chief, but not only, focus for BRG in improving commercial effectiveness is by gaining and maintaining US and global market access. I have held industry leadership positions in the East Coast, California, and in Europe at, respectively, Synageva, ALZA and Amgen. In addition to over 10 years of experience in industry and several years in consulting, I spent a decade at RAND. My doctorate is in Economics from the Stanford Graduate School of Business.

Justin Stindt, Justin Stindt Consulting

I am managing director of the consultancy Justin Stindt Consulting. My team and I support pharma and biotech clients with Market Access strategy and execution. This includes strategy development, payer insight & engagement and project management support to produce local MA deliverables. I have worked in various Market Access and Commercial Director roles at GlaxoSmithKline with international responsibilities for Market Access and pricing strategies, evidence generation to meet payer requirements, product launches and commercial strategy for pipeline assets. Our key difference is that we deliver specific, in-depth insight on payer resonating evidence to create robust value propositions and strategies. We operate out of offices in Paris and Cologne and have a global reach through our network of payers, clinical experts and partners..

Joel Owerbach, Pharmaceutical Strategy Solutions

I am a consultant working on pharmaceutical strategy solutions. I have over 40 years of experience in U.S. managed care pharmacy. I was most recently Vice President, Health Policy-Strategy for Alliance Life Sciences Consulting Group (ALSCG), a global innovative management and technology consultancy, and formerly Vice President, Chief Pharmacy Officer, for Excellus Health Plans, headquartered in Rochester, NY.

As one of the early innovators in the development of clinical pharmacy programs within managed care, I have pioneered numerous clinical management and specialty programs, including Drug Information (1977), Pharmacokinetic evaluation program (1978), Anticoagulation Services (1979), Home Intravenous Therapy Service (1982), and Terminal Care/hospice programs (1984) among others. I work with a number of pharmaceutical companies, assessing US pharmaceutical market access potential for Phase 1-3 drugs, including specialty products, orphan drugs, and biosimilars. I have participated in and managed multiple advisory boards and has developed databases and applications profiling and tracking the new Health Care Exchange payer, benefits, and formulary information.